MedTrace Logo

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES

NCT03658135 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2019-12-19

No results posted yet for this study

Summary

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients with Four Different Primary Tauopathy Syndromes

Conditions

  • Primary Tauopathies
  • Corticobasal Degeneration Syndrome
  • Frontotemporal Lobar Degeneration With Tau Inclusions
  • MAPT Mutation Carriers, Symptomatic
  • Traumatic Encephalopathy Syndrome
  • Nonfluent Aphasia, Progressive

Interventions

DRUG

BIIB092

BIIB092 is an investigational monoclonal antibody directed at tau protein

OTHER

Placebo

Inactive ingredient

Sponsors & Collaborators

Principal Investigators

  • Adam Boxer, MD, PhD · UCSF Memory and Aging Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-12
Primary Completion
2019-12-13
Completion
2019-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03658135 on ClinicalTrials.gov